Detalles de la búsqueda
1.
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Blood
; 141(14): 1666-1674, 2023 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564045
2.
Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
Proc Natl Acad Sci U S A
; 118(17)2021 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33883278
3.
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Br J Haematol
; 201(5): 845-850, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36895158
4.
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Br J Haematol
; 201(2): 267-279, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541152
5.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Blood
; 136(9): 1091-1104, 2020 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32438407
6.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33428632
7.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32656799
8.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33910333
9.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32499244
10.
Subclonal TP53 copy number is associated with prognosis in multiple myeloma.
Blood
; 132(23): 2465-2469, 2018 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373884
11.
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(1): 57-73, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30559051
12.
Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS).
Radiology
; 291(1): 5-13, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30806604
13.
Redefining nonmeasurable multiple myeloma using mass spectrometry.
Blood
; 139(6): 946-950, 2022 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34871382
14.
Neutral tumor evolution in myeloma is associated with poor prognosis.
Blood
; 130(14): 1639-1643, 2017 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28827410
15.
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Haematologica
; 104(7): 1440-1450, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30733268
16.
Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI.
Eur Radiol
; 28(4): 1687-1691, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29134357
17.
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.
Blood
; 125(5): 831-40, 2015 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-25428216
18.
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
Blood
; 125(19): 2985-94, 2015 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-25805812
19.
Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.
BMC Cancer
; 17(1): 718, 2017 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29110637
20.
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.
Blood
; 123(22): 3414-9, 2014 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-24733348